Literature DB >> 17519122

Compliance and fixed-dose combination therapy.

Sripal Bangalore1, Anupama Shahane, Sanobar Parkar, Franz H Messerli.   

Abstract

Despite data on the importance of blood pressure control in preventing cardiovascular and cerebrovascular events, only 34% of hypertensive patients have their blood pressure under control. The National Council on Patient Information and Education has estimated that the compliance rate is just over 30% for chronic conditions like hypertension. Polypharmacy and complex treatment regimens have been identified as important, modifiable risk factors for medication noncompliance. Fixed-dose combination regimens are attractive options because of the improved antihypertensive efficacy resulting from the dual mechanistic action of components targeting different effector mechanisms. One drug in the fixed-dose combination may negate an adverse effect of the other medication. Above all, fixed-dose combination therapy reduces pill burden and improves medication compliance, which can translate into better cardiovascular outcomes. Fixed-dose combinations should be used routinely for the management of hypertension and should also be considered when initiating therapy for patients with newly diagnosed hypertension.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17519122     DOI: 10.1007/s11906-007-0033-3

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   4.592


  39 in total

1.  Pedal edema--not all dihydropyridine calcium antagonists are created equal.

Authors:  Franz H Messerli; Ehud Grossman
Journal:  Am J Hypertens       Date:  2002-11       Impact factor: 2.689

Review 2.  Overcoming barriers to effective blood pressure control in patients with hypertension.

Authors:  Rainer Düsing
Journal:  Curr Med Res Opin       Date:  2006-08       Impact factor: 2.580

3.  Global burden of hypertension: analysis of worldwide data.

Authors:  Patricia M Kearney; Megan Whelton; Kristi Reynolds; Paul Muntner; Paul K Whelton; Jiang He
Journal:  Lancet       Date:  2005 Jan 15-21       Impact factor: 79.321

Review 4.  Achieving blood pressure targets in the management of hypertension.

Authors:  B Waeber
Journal:  Blood Press Suppl       Date:  2001

Review 5.  Managing the patient with hard-to-control hypertension.

Authors:  S Oparil; D A Calhoun
Journal:  Am Fam Physician       Date:  1998-03-01       Impact factor: 3.292

6.  Foot volume increase on nifedipine is not prevented by pretreatment with diuretics.

Authors:  Antoine G van der Heijden; Frans Th M Huysmans; Henk W van Hamersvelt
Journal:  J Hypertens       Date:  2004-02       Impact factor: 4.844

7.  Initiation of hypertension treatment with a fixed-dose combination or its monocomponents -- does it really matter?

Authors:  J Scholze; M Bida; A Hansen; D Juncken; B Rangoonwala; A Ritz; J Schnitker; Y Dörffel
Journal:  Int J Clin Pract       Date:  2006-03       Impact factor: 2.503

8.  Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.

Authors:  Peter Gaede; Pernille Vedel; Nicolai Larsen; Gunnar V H Jensen; Hans-Henrik Parving; Oluf Pedersen
Journal:  N Engl J Med       Date:  2003-01-30       Impact factor: 91.245

9.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

10.  A strategy to reduce cardiovascular disease by more than 80%.

Authors:  N J Wald; M R Law
Journal:  BMJ       Date:  2003-06-28
View more
  16 in total

Review 1.  Hypertension in African Americans.

Authors:  Nomsa Musemwa; Crystal A Gadegbeku
Journal:  Curr Cardiol Rep       Date:  2017-10-28       Impact factor: 2.931

2.  Herbal Fixed Dose Combinations in Nepal: Growing Concerns in a Developing Country.

Authors:  Arjun Poudel; Kadir Alam; Subish Palaian; Mohamed Izham Mohamed Ibrahim
Journal:  J Clin Diagn Res       Date:  2016-10-01

Review 3.  Triple Combination Therapies Based on Olmesartan: A Personalized Therapeutic Approach to Improve Blood Pressure Control.

Authors:  Massimo Volpe; Caterina Santolamazza; Vittoria Mastromarino; Roberta Coluccia; Allegra Battistoni; Giuliano Tocci
Journal:  High Blood Press Cardiovasc Prev       Date:  2017-06-12

4.  Effectiveness and tolerability of fixed-dose combination enalapril plus nitrendipine in hypertensive patients: results of the 3-month observational, post-marketing, multicentre, prospective CENIT study.

Authors:  Alejandro de la Sierra; Alejandro Roca-Cusachs; Josep Redón; Rafael Marín; Manuel Luque; Mariano de la Figuera; Margarida Garcia-Garcia; Liliana Falkon
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

5.  Safety and tolerability of fixed antihypertensive combinations in blood pressure control: focus on olmesartan medoxomil and amlodipine combination.

Authors:  Ijlal Uddin; Shakil Aslam
Journal:  Integr Blood Press Control       Date:  2010-11-16

6.  Antihypertensive combination therapy in primary care offices: results of a cross-sectional survey in Switzerland.

Authors:  Susanne Roas; Felix Bernhart; Michael Schwarz; Walter Kaiser; Georg Noll
Journal:  Int J Gen Med       Date:  2014-12-09

7.  Efficacy and safety of valsartan/amlodipine single-pill combination in 11,422 Chinese patients with hypertension: an observational study.

Authors:  Dayi Hu; Lisheng Liu; Weimin Li
Journal:  Adv Ther       Date:  2014-07-02       Impact factor: 3.845

Review 8.  Phentermine and topiramate for the management of obesity: a review.

Authors:  Gina Cosentino; Ariane O Conrad; Gabriel I Uwaifo
Journal:  Drug Des Devel Ther       Date:  2011-04-05       Impact factor: 4.162

9.  A novel programme to evaluate and communicate 10-year risk of CHD reduces predicted risk and improves patients' modifiable risk factor profile.

Authors:  J S Benner; L Erhardt; M Flammer; R A Moller; N Rajicic; K Changela; C Yunis; S B Cherry; Z Gaciong; E S Johnson; M C J M Sturkenboom; J García-Puig; X Girerd
Journal:  Int J Clin Pract       Date:  2008-08-07       Impact factor: 2.503

10.  Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study.

Authors:  Arya M Sharma; Jaime Davidson; Stephen Koval; Yves Lacourcière
Journal:  Cardiovasc Diabetol       Date:  2007-10-02       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.